

REMARKS

Claims 1-26 are pending in this application. Claim 16 was amended to correct a minor typographical error. Claims 20-26 are withdrawn from consideration pending possible rejoinder.

The Examiner required restriction to one of the following groups:

Group I (claims 1-19) drawn to drug-containing nanoparticles;

Group II (claims 20-21) drawn to a trans-dermal or trans-mucus external preparation;

Group III (claim 22) drawn to an injectable preparation;

Group IV (claim 23 and 25-26) drawn to a process of producing drug-containing nanoparticles; and

Group V (claim 24 and 25-26) drawn to a process of producing drug-containing nanoparticles.

Applicants hereby elect to prosecute the claims of Group I (Claims 1-19). Claims 20-26 are withdrawn pending rejoinder or re-filing in a divisional application.

Application No. 10/596,828
Amendment dated Feb. 25, 2008
Reply to Non-Final Office Action of Jan. 23, 2008

If the Examiner has any questions, he is respectfully requested to contact the undersigned. The Commissioner is hereby authorized to charge any additional fees, or to credit any overpayment, to Deposit Account No. 50-3195.

Respectfully submitted,

Date: February 25, 2008

/Manette Dennis/
Manette Dennis (Reg. No. 30,623)
Ostrager Chong Flaherty & Broitman, PC
570 Lexington Avenue, Floor 17
New York, NY 10022-6894
Tel.: 212 681-0600
Fax: 212 681-0300
mdennis@ocfbllaw.com